JP2017508817A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508817A5
JP2017508817A5 JP2017501116A JP2017501116A JP2017508817A5 JP 2017508817 A5 JP2017508817 A5 JP 2017508817A5 JP 2017501116 A JP2017501116 A JP 2017501116A JP 2017501116 A JP2017501116 A JP 2017501116A JP 2017508817 A5 JP2017508817 A5 JP 2017508817A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
intrahepatic cholestasis
compound
methylphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017501116A
Other languages
English (en)
Japanese (ja)
Other versions
JP6568577B2 (ja
JP2017508817A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/021502 external-priority patent/WO2015143178A1/en
Publication of JP2017508817A publication Critical patent/JP2017508817A/ja
Publication of JP2017508817A5 publication Critical patent/JP2017508817A5/ja
Application granted granted Critical
Publication of JP6568577B2 publication Critical patent/JP6568577B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017501116A 2014-03-20 2015-03-19 肝内胆汁うっ滞症の治療 Active JP6568577B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461968037P 2014-03-20 2014-03-20
US61/968,037 2014-03-20
PCT/US2015/021502 WO2015143178A1 (en) 2014-03-20 2015-03-19 Treatment of intrahepatic cholestatic diseases

Publications (3)

Publication Number Publication Date
JP2017508817A JP2017508817A (ja) 2017-03-30
JP2017508817A5 true JP2017508817A5 (enExample) 2018-04-19
JP6568577B2 JP6568577B2 (ja) 2019-08-28

Family

ID=52808186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017501116A Active JP6568577B2 (ja) 2014-03-20 2015-03-19 肝内胆汁うっ滞症の治療

Country Status (32)

Country Link
US (5) US9486428B2 (enExample)
EP (1) EP3119384B1 (enExample)
JP (1) JP6568577B2 (enExample)
KR (1) KR102000332B1 (enExample)
CN (1) CN106102734B (enExample)
AU (1) AU2015231232B2 (enExample)
BR (1) BR112016020260A8 (enExample)
CA (1) CA2941401C (enExample)
CL (1) CL2016002338A1 (enExample)
CY (1) CY1120927T1 (enExample)
DK (1) DK3119384T3 (enExample)
EA (1) EA032358B1 (enExample)
ES (1) ES2701094T3 (enExample)
FI (1) FIC20253004I1 (enExample)
FR (1) FR25C1031I1 (enExample)
HR (1) HRP20181914T1 (enExample)
HU (2) HUE041733T2 (enExample)
IL (1) IL247920B (enExample)
LT (2) LT3119384T (enExample)
MX (1) MX367478B (enExample)
NL (1) NL301338I2 (enExample)
NO (1) NO2025035I1 (enExample)
NZ (1) NZ724057A (enExample)
PH (1) PH12016501769A1 (enExample)
PL (1) PL3119384T3 (enExample)
PT (1) PT3119384T (enExample)
RS (1) RS57970B1 (enExample)
SI (1) SI3119384T1 (enExample)
SM (1) SMT201800690T1 (enExample)
UA (1) UA120756C2 (enExample)
WO (1) WO2015143178A1 (enExample)
ZA (1) ZA201606043B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110091680A (ko) 2008-10-17 2011-08-12 메타볼렉스, 인코포레이티드 작고 조밀한 ldl 입자를 감소시키는 방법
US10272058B2 (en) * 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
UA121208C2 (uk) 2014-04-11 2020-04-27 Сімабей Терапьютікс, Інк. Лікування нажхп та насг
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
LT3973959T (lt) * 2017-09-26 2025-01-10 Cymabay Therapeutics, Inc. Cholestazinio niežulio gydymas seladelparu
EP3880187A1 (en) * 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
JP7731868B2 (ja) 2019-08-02 2025-09-01 エースロット,インコーポレイテッド TDP-43、α-シヌクレイン、ハンチンチンタンパク質及びタウタンパク質のオリゴマー形成に関連する疾患を治療するための小分子薬物、並びに関連する方法
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
SMT202400302T1 (it) 2021-02-01 2024-09-16 Cymabay Therapeutics Inc Trattamento di colangiopatie con seladelpar

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
ATE327244T1 (de) 1995-03-06 2006-06-15 Isis Pharmaceuticals Inc Verfahren zur synthese von 2'-0-substituierten pyrimidinen und oligomere davon
BR9707529A (pt) 1996-02-14 2000-01-04 Isis Pharmaceuticals Inc Oligunucleotìdeo especificamente hibridizável com dna ou rna.
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
SI1667964T1 (sl) 2003-09-19 2009-12-31 Janssen Pharmaceutica Nv 4-((fenoksialkil)tio)-fenoksiocetne kisline in analogi
CA2910191C (en) 2004-03-05 2022-03-08 The Trustees Of The Univeristy Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
KR20110091680A (ko) 2008-10-17 2011-08-12 메타볼렉스, 인코포레이티드 작고 조밀한 ldl 입자를 감소시키는 방법
MA34097B1 (fr) 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
EA201691039A1 (ru) 2013-11-20 2016-11-30 Саймабэй Терапьютикс, Инк. Лечение гомозиготной семейной гиперхолестеринемии
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
UA121208C2 (uk) 2014-04-11 2020-04-27 Сімабей Терапьютікс, Інк. Лікування нажхп та насг
CN106470675A (zh) 2014-06-26 2017-03-01 西玛贝医药公司 严重高甘油三酯血症的治疗
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
LT3973959T (lt) 2017-09-26 2025-01-10 Cymabay Therapeutics, Inc. Cholestazinio niežulio gydymas seladelparu
KR20210092754A (ko) 2018-11-16 2021-07-26 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash의 병용 치료
EP3880187A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications

Similar Documents

Publication Publication Date Title
JP2017508817A5 (enExample)
JP2017513836A5 (enExample)
JP2017505285A5 (enExample)
JP2018534348A5 (enExample)
HRP20192299T1 (hr) Liječenje nafld i nash
JP2014507446A5 (enExample)
JP2020535225A5 (enExample)
JP2017537066A5 (enExample)
JP2012193216A5 (enExample)
JP2014515013A5 (enExample)
JP2014511891A5 (enExample)
JP2013525444A5 (enExample)
JP2009530398A5 (enExample)
JP2016510326A5 (enExample)
JP2016534063A5 (enExample)
JP2016511753A5 (enExample)
JP2015510916A5 (enExample)
JP2015038135A5 (enExample)
JP2014511374A5 (enExample)
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
JP2018537507A5 (enExample)
NZ724057A (en) Treatment of intrahepatic cholestatic diseases
JP2014521641A5 (enExample)
JP2017505809A5 (enExample)
JP2015516419A5 (enExample)